Navigation Links
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
Date:2/13/2008

Assets

Current assets:

Cash and cash equivalents $75,963 $87,905

Short-term investments 357,531 202,008

Trade accounts receivable, net of

allowance for doubtful accounts of

$719 and $670 at December 31, 2007

and December 31, 2006, respectively 32,678 25,880

Accounts receivable - other 11,044 1,646

Inventories 48,540 52,056

Deferred income tax - short term 8,825 7,247

Prepaid income tax 2,390 -

Prepaid expenses 17,505 11,362

Other current assets 4,402 2,583

Total current assets 558,878 390,687

Property, plant and equipment, net 129,493 134,614

Capitalized software 15,923 18,437

Goodwill 18,621 18,621

Deferred income tax - long term 7,942 2,064

License, manufacturing access fees and

other assets 58,196 59,416

Total assets $789,053 $623,839

Liabilities and stockholders' equity

Current liabilities:

Accounts payable $11,777 $13,586

Accrued salaries and employee benefits 20,997 16,723

Other accrued expenses 4,014 3,320

Income tax payable 846 14,075

Deferred revenue 2,836 921

Total current liabilities 40,470 48,625

Non-current income tax payable
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Carl Hull Named President and Chief Operating Officer of Gen-Probe
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
5. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
6. Imagenetix Inc. Reports Third Fiscal Quarter Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email: